Literature DB >> 28529203

Bedaquiline as a potential agent in the treatment of Mycobacterium abscessus infections.

Silvan Vesenbeckh1, Nicolas Schönfeld2, Andreas Roth3, Gudrun Bettermann4, David Krieger2, Torsten Thomas Bauer2,5, Holger Rüssmann4, Harald Mauch4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28529203     DOI： 10.1183/13993003.00083-2017

Source DB:  PubMed          Journal:  Eur Respir J        ISSN： 0903-1936            Impact factor:   16.671


× No keyword cloud information.
  11 in total

1.  Effect of Amoxicillin in combination with Imipenem-Relebactam against Mycobacterium abscessus.

Authors:  Rose C Lopeman; James Harrison; Daniel L Rathbone; Maya Desai; Peter A Lambert; Jonathan A G Cox
Journal:  Sci Rep       Date:  2020-01-27       Impact factor: 4.379

2.  Mutations in the MAB_2299c TetR Regulator Confer Cross-Resistance to Clofazimine and Bedaquiline in Mycobacterium abscessus.

Authors:  Matthias Richard; Ana Victoria Gutiérrez; Albertus Viljoen; Daniela Rodriguez-Rincon; Françoise Roquet-Baneres; Mickael Blaise; Isobel Everall; Julian Parkhill; R Andres Floto; Laurent Kremer
Journal:  Antimicrob Agents Chemother       Date:  2018-12-21       Impact factor: 5.191

3.  The TetR Family Transcription Factor MAB_2299c Regulates the Expression of Two Distinct MmpS-MmpL Efflux Pumps Involved in Cross-Resistance to Clofazimine and Bedaquiline in Mycobacterium abscessus.

Authors:  Ana Victoria Gutiérrez; Matthias Richard; Françoise Roquet-Banères; Albertus Viljoen; Laurent Kremer
Journal:  Antimicrob Agents Chemother       Date:  2019-09-23       Impact factor: 5.191

4.  In Vitro Bedaquiline and Clofazimine Susceptibility Testing in Mycobacterium abscessus.

Authors:  Bettina Schulthess; Fatma Nur Akdoğan Kittana; Rico Hömke; Peter Sander
Journal:  Antimicrob Agents Chemother       Date:  2022-04-14       Impact factor: 5.938

Review 5.  Pipeline of anti-Mycobacterium abscessus small molecules: Repurposable drugs and promising novel chemical entities.

Authors:  Anna Egorova; Mary Jackson; Victor Gavrilyuk; Vadim Makarov
Journal:  Med Res Rev       Date:  2021-03-01       Impact factor: 12.388

Review 6.  Recent advances in nontuberculous mycobacterial lung infections.

Authors:  David Horne; Shawn Skerrett
Journal:  F1000Res       Date:  2019-10-01

Review 7.  Alternative and Experimental Therapies of Mycobacterium abscessus Infections.

Authors:  Michal Meir; Daniel Barkan
Journal:  Int J Mol Sci       Date:  2020-09-16       Impact factor: 5.923

Review 8.  Bioenergetics of Mycobacterium: An Emerging Landscape for Drug Discovery.

Authors:  Iram Khan Iqbal; Sapna Bajeli; Ajit Kumar Akela; Ashwani Kumar
Journal:  Pathogens       Date:  2018-02-23

9.  Determination of MIC Distribution and Mechanisms of Decreased Susceptibility to Bedaquiline among Clinical Isolates of Mycobacterium abscessus.

Authors:  Bing Li; Meiping Ye; Qi Guo; Zhemin Zhang; Shiyi Yang; Wei Ma; Fangyou Yu; Haiqing Chu
Journal:  Antimicrob Agents Chemother       Date:  2018-06-26       Impact factor: 5.191

10.  Population Pharmacokinetic Analysis of Bedaquiline-Clarithromycin for Dose Selection Against Pulmonary Nontuberculous Mycobacteria Based on a Phase 1, Randomized, Pharmacokinetic Study.

Authors:  Ken Kurosawa; Stefaan Rossenu; Jeike Biewenga; Sivi Ouwerkerk-Mahadevan; Wouter Willems; Etienne Ernault; Chrispin Kambili
Journal:  J Clin Pharmacol       Date:  2021-06-12       Impact factor: 3.126
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.